YIH
ANIX icon

Y-Intercept (HK)’s Anixa Biosciences ANIX Stock Holding History

Y-Intercept (HK)’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,372
Closed -$55.8K – 1336
2023
Q4 		$55.8K Buy
+14,372
New +$48.5K 0.01% 1150

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Y-Intercept (HK)'s ANIX Position: Q1 2024 in Review

Y-Intercept (HK) sold out of Anixa Biosciences (ANIX) in Q1 2024, closing a stake of 14,372 shares — an estimated $55.8K sold.

Y-Intercept (HK) first reported a position in ANIX in Q4 2023 and held it in 1 quarter. The position peaked at $55.8K in Q4 2023. 58 funds tracked by Wall St. Rank hold ANIX as of Q1 2024.

  • Y-Intercept (HK) reported no remaining Anixa Biosciences position as of Q1 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 14,372 Anixa Biosciences shares in Q1 2024, an estimated $55.8K.
  • Y-Intercept (HK) first reported a position in Anixa Biosciences in Q4 2023 and held it in 1 quarter.
  • Y-Intercept (HK)'s Anixa Biosciences position peaked at $55.8K in Q4 2023.
  • 58 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2024.

Based on Y-Intercept (HK)'s 13F filing for Q1 2024, filed 10 May 2024.